2nd Quarter - Report
THE MCMANUS GROUP for GILEAD SCIENCES, INC.
Firm
Client
Income
$60,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Support for EPIC Act - S. 839, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
Health Issues HCR
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to federal funding for HIV prevention.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.